FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma

On August 16, 2018, the U.S. Food and Drug Administration approved lenvatinib (Lenvima, Eisai Inc.) for first‐line treatment of patients with unresectable hepatocellular carcinoma (HCC). Approval was based on an international, multicenter, randomized, open‐label, noninferiority trial (REFLECT; NCT01...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Nair, Abhilasha, Reece, Kelie, Donoghue, Martha B., Yuan, Weishi (Vivian), Rodriguez, Lisa, Keegan, Patricia, Pazdur, Richard
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Inc. 2020
Soggetti:
Regulatory Issues: FDA
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7930400/
https://ncbi.nlm.nih.gov/pubmed/33044793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13566
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi